Alkermes’ alixorexton secures FDA and EC orphan designations
The FDA granted the status to alixorexton for idiopathic hypersomnia while the EC approved the designation for narcolepsy.
Drug Development
Simcere and Stanford partner to develop IPF therapies
FDA clears MSD’s Keytruda combo plus Welireg for ccRCC treatment
China’s NMPA approves Akeso’s gumokimab for plaque psoriasis
FDA grants priority review for Roche’s Tecentriq combo sBLA
XtalPi enters $400m partnership for small molecule therapy for GPCR target
EMA validates Bayer’s asundexian application for ischaemic stroke
Coya Therapeutics CEO on ALS urgency and fast-tracking COYA 302 for patient impact
